HSV-1 and HSV-2 Nucleic Acid Detection Using Transcription-Mediated Amplification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for Herpes Simplex Virus (HSV) infections, particularly HSV-1 and HSV-2, face challenges such as low sensitivity, delayed results, and inability to differentiate between types, leading to inadequate treatment and transmission control.
Innovation Solution
A method involving the amplification of viral nucleic acid using transcription-mediated amplification (TMA) targeting the UL42 open reading frame (ORF) specific to HSV-1 and HSV-2, allowing for rapid, specific, and sensitive detection, including the use of oligomers and probes to distinguish between the two types.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If viral culture is used for HSV diagnosis, then detection capability is improved, but detection time is delayed (takes 3 days) and sensitivity is reduced in older lesions
Solution Approach 1:
The patent applies preliminary action by performing nucleic acid extraction and amplification immediately upon sample receipt, before the virus can be cultured. The TMA reaction is initiated promptly to amplify viral RNA, producing detectable signals within hours rather than waiting 3 days for culture growth. This preliminary processing of the sample dramatically reduces detection time while maintaining high sensitivity.
2Reliability
If serological tests are used for HSV diagnosis, then sensitivity is improved, but specificity is reduced due to false positives and timing delays
Solution Approach 1:
The patent extracts and detects viral nucleic acids directly from clinical samples, separating the detection target from the host cellular components. By focusing the assay specifically on viral RNA sequences through TMA amplification, the test achieves both high sensitivity for detecting infection and high specificity by ignoring non-viral substances in the sample, thereby eliminating false positives that plague serological tests.
Solution Approach 2:
The patent replaces the immune-based mechanical system (antibody-antigen interaction in serology) with a molecular system (nucleic acid amplification and detection). This substitution allows direct detection of viral genetic material, providing immediate results without the timing delays and false positives inherent in serological responses, thereby improving both sensitivity and specificity simultaneously.
3Measurement precision
If type-specific primers are used for PCR, then differentiation between HSV-1 and HSV-2 is improved, but assay complexity increases
Solution Approach 1:
The patent segments the UL42 gene region into distinct diagnostic zones with unique nucleotide sequences for HSV-1 and HSV-2. By targeting specific segmented regions rather than the entire genome, the assay achieves clear differentiation between virus types through type-specific primers and probes, while keeping the amplified product size manageable and the overall assay structure relatively simple.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables rapid and accurate detection of HSV-1 and HSV-2, facilitating timely treatment and reducing infection transmission by providing a method for differentiating between the two types within a short timeframe.
Implementation Method 1
A method involving the amplification of viral nucleic acid using transcription-mediated amplification (TMA) targeting the UL42 open reading frame (ORF) specific to HSV-1 and HSV-2
Implementation Method 2
The methods involve the amplification of viral nucleic acid to detect the HSV target sequence in the sample
Data Source
Figure 1A
Figure 1B
Figure 1C
AI summary
There is disclosed a method for determining the presence or absence of Herpes Simplex Virus 1 (HSV-1) or Herpes Simplex Virus 2 (HSV-2) in a sample, said method comprising: contacting a sample, said sample suspected of containing HSV-1 or HSV-2, with at least two oligomers for amplifying a target region of an HSV-1 target nucleic acid and at least two oligomers for amplifying a target region of an HSV-2 target nucleic acid, wherein the at least two amplification oligomers for amplifying a target region of an HSV-1 target nucleic acid comprise a first amplification oligomer comprising a first target-hybridizing sequence that is from about 15 to about 27 contiguous nucleotides contained in the sequence of SEQ ID NO:31 and that includes at least the sequence of SEQ ID NO:30; and a second amplification oligomer comprising a second target-hybridizing sequence that is from about 15 to about 27 contiguous nucleotides contained in the sequence of SEQ ID NO:33 and that includes at least the sequence of SEQ ID NO:32; and wherein the at least two amplification oligomers for amplifying a target region of an HSV-2 target nucleic acid comprise a third amplification oligomer comprising a third target-hybridizing sequence that is from about 15 to about 27 contiguous nucleotides (i) contained in the sequence of SEQ ID NO:49 and that includes at least the sequence of SEQ ID NO:48 or (ii) contained in the sequence of SEQ ID NO:43 and that includes at least the sequence of SEQ ID NO:42; and a fourth amplification oligomer comprising a fourth target-hybridizing sequence that is from about 15 to about 27 contiguous nucleotides (i) contained in the sequence of SEQ ID NO:51 and that includes at least the sequence of SEQ ID NO:50 or (ii) contained in the sequence of SEQ ID NO:45 and that includes at least the sequence of SEQ ID NO:44.